Patients must not be known to be refractory to red blood cell or platelet transfusions
Hemoglobin ? 10 g/dL with no blood transfusions (packed red blood cells and platelet transfusions) in the past 28 days, within 28 days prior to administration of study treatment
Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable
Whole blood transfusions in the last 120 days prior to entry to the study which may interfere with gBRCA testing (packed red blood cells and platelet transfusions are acceptable)
Platelet count >= 100,000/uL; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility
No platelet transfusions within 7 days of registration to meet eligibility criteria; Note: red blood cell transfusions are allowed at any time
Transfusions are permitted to meet both the platelet and hemoglobin criteria; patients must not be known to be refractory to red blood cell or platelet transfusions
Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable)
Platelet count >= 75 x 10^9/L; subjects may receive red blood cells (RBC) transfusions or platelet transfusions, if clinically indicated in accordance with institutional guidelines; however, screening platelet count should be independent of platelet transfusions for at least 2 weeks
Pts may receive RBC or platelet transfusions, if clinically indicated, in accordance with institutional guidelines
Use of red blood cell or platelet transfusions within 4 weeks of treatment
Platelets ?100×109/L (w/o transfusions w/in 21 days)
Platelets >= 100,000/mcL (not requiring platelet transfusions)
Platelets >= 50,000/mm^3 for MCL cohort and platelets >= 75,000/mm^3 for DLBCL cohort, performed within 14 days prior to day 1 of protocol therapy\r\n* NOTE: platelet transfusions and packed red blood cell transfusion can be given prior to enrollment to achieve a target platelet (Plt) >= 50,000/uL for MCL and >= 75,000/uL for DLBCL and hemoglobin of >= 8.5 g/dL
Whole blood transfusions in the last 120 days prior to entry to the study
Hematologic function, as follows (no red blood cell or platelet transfusions are allowed within 14 days of the first dose of enfortumab vedotin):
Within two weeks prior to enrollment: Not refractory to red cell or platelet transfusions
Patients should not be known to be refractory to red blood cell or platelet transfusions
Patients must be transfusion independent (i.e., no blood product transfusions for a period of at least 14 days prior to screening)
Subjects must be transfusion independent (i.e., no blood product transfusions for a period of at least 14 days prior to screening).
Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable)
Platelets >= 75,000/mm^3 (transfusions not permitted within 7 days of screening)
Patients known to be refractory to platelet or packed red cell transfusions per Institutional Guidelines, or a patient who refuses blood product support.
Within 14 days prior to planned start of treatment: Platelets >= 100,000/mm^3\r\n* Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
Platelets >= 100,000/mcL (not requiring platelet transfusions)
Whole blood transfusions in the last 120 days
Transfusion independent (no red blood cell or platelet transfusions in the preceding 2 weeks of screening)
PHASE I: No blood transfusions 28 days prior to study entry
PHASE II: No blood transfusions 28 days prior to study entry
Patients refractory to red blood cell or platelet transfusions
Patients who refuse to receive blood transfusions
ANC >= 500 X 10^9 /L with transfusions allowed if stem cells available
Platelets >= 20,000 X 10^9 /L with transfusions allowed if stem cells available
Hemoglobin >= 8.0 g/dL with transfusions allowed if stem cells available; patients with stem cells available are excluded if they require two platelet transfusions per week to maintain the minimum required platelet count; a bone marrow examination is not medically indicated for patients diagnosed with metastatic pheochromocytoma
Platelet count should be > 50,000/ul and hemoglobin should be > 8 gm/dl; patients may receive platelet or red blood cell transfusions to maintain hemoglobin and platelets at clinical appropriate levels
Willing to undergo blood transfusions as deemed clinically necessary.
Patients who have received no less than 20 transfusions of RBCs;
Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable).
Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable)
Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Platelets >= 75,000/mm^3\r\n* NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
To be performed within 28 days prior to day 1 of protocol therapy: Platelets >= 75,000/mm^3 without transfusions
Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable)
Patients on Part A1 or Part C of the study:\r\n* For patients with solid tumors or ALCL without bone marrow involvement:\r\n** Peripheral absolute neutrophil count (ANC) >= 1,000/mm^3\r\n** Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)\r\n** Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)\r\n* Patients with known bone marrow metastatic disease: \r\n** Peripheral absolute neutrophil count (ANC) >= 750/mm^3\r\n** Platelet count >= 25,000/mm^3 (may receive platelet transfusions)\r\n** Hemoglobin >= 8.0 g/dL (may receive RBC transfusions)\r\n** Not known to be refractory to RBC or platelet transfusions\r\nTransfusions are permitted to meet both the platelet and hemoglobin criteria; Note: patients with known bone marrow metastatic disease are not evaluable for hematological toxicity for the purposes of dose escalation
Patients eligible for Part A2, Part A3, or Part B of the study must meet the hematologic criteria below for enrollment:\r\n* Peripheral absolute neutrophil count (ANC) >= 750/mm^3\r\n* Platelet count >= 25,000/mm^3 (may receive platelet transfusions)\r\n* Hemoglobin >= 8.0 g/dL (may receive RBC transfusions)\r\n* Not known to be refractory to red cell or platelet transfusions\r\nTransfusions are permitted to meet both the platelet and hemoglobin criteria
Platelet count ?20,000/µL (Transfusions to achieve this level are allowed).
Anemia that requires red blood cell transfusions
Patients in CRi must have evidence of hematologic recovery after prior therapy independent of red blood cell transfusions
blood transfusions prior to 1990,
Platelet count > 100 x 10^9/L (30 x 10^9/L if myeloma involvement in the bone marrow aspirate is > 50%) within 30 days prior to cycle 1 day 1; subjects may receive platelet transfusions within institutional guidelines
Patients should not have received any platelet transfusions in the last 4 weeks before screening date
Platelet count >= 50 x 10^9/L (>= 30 x 10^9/L if myeloma involvement in the bone marrow is > 50%) within 14 days prior to initial treatment (subjects may be receiving platelet transfusions in accordance with institutional guidelines)
Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable.
Requirement for platelet transfusions.
History of 15 to 75 PRBC transfusions
More than 6 months of cumulative iron-chelation therapy (such as daily deferasirox (Exjade) or deferiprone or 5x/week deferosamine). intermittent deferoxamine doses in association with blood transfusions are not exclusionary regardless of duration of such treatment. -- More than 3 years since patient began receiving regular transfusions (2 units per 8 weeks or 4 units received in a 3 month period).
Active immune thrombocytopenic purpura or history of being refractory to platelet transfusions (within 1 year of first dose)
Patients refractory to red blood cell or platelet transfusions
Subject has received blood transfusions or hematopoietic factor therapy within 14 days prior to the first dose of study drug.
Blood transfusions or hemopoietic factor therapy
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients are known to be refractory to red blood cell or platelet transfusions
NON-PROGRESSED DIPG (STRATUM 2): Patients are known to be refractory to red blood cell or platelet transfusions
Patients with leukemia must not be known to be refractory to red blood cell or platelet transfusions.
Platelets >= 50,000/mm^3 or 30,000 (if marrow infiltrated with myeloma; no platelet transfusions are allowed in the 7 days prior to screening)
Adequate renal, hepatic, and bone marrow function without frequent blood product or hematopoietic growth factor support (eg use of erythropoietin or transfusions > 2 units packed red blood cells every 3 months)
Platelets ? 75 x 109/L without transfusions within 21 days before 1st treatment.
Platelet count of =< 50 x 10^9/L less than 7 days before enrollment; platelet transfusions are permitted to reach entry criteria but should be discussed on a case-by-case basis with the study principal investigator (PI) and permission will depend on etiology of the thrombocytopenia, if not felt to be due to MM
No platelet or blood transfusions within two weeks of obtaining baseline laboratory values
Patients may receive RBC or platelet transfusions, if clinically indicated, in accordance with institutional guidelines
Adequate bone marrow function defined as absolute neutrophil count (ANC) >=1000/microliter, hemoglobin >=8.0 gram per deciliter (g/dL) (may receive red blood cell transfusions), platelets >=75,000/ microliter (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment).
Must have adequate organ function as defined by the following values: Adequate bone marrow function defined as-absolute neutrophil count (ANC) >=1000/ microliter (µL), hemoglobin >=8.0 grams (g)/ deciliter (dL) (may receive red blood cell transfusions), platelets >=75,000/µL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment).
Blood transfusions or hemopoietic factor therapy
Subjects for whom prophylactic platelet transfusions, at platelet counts >10× 109/L, are anticipated following PBSC transplant
Platelet count >= 100 X 10^9/L w/o blood transfusions for 7 days preceding lab assessment, obtained within 14 days prior to PET scan
* Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)
For patients with solid tumors without known bone marrow involvement: hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin >= 10.0 g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions) for patients with solid tumors without bone marrow involvement
Hemoglobin > 8 g/dL (prior red blood cell [RBC] transfusion allowed); patients may be transfused to achieve this value
Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell [RBC] transfusion is permitted).
Red Blood cell transfusion dependent (defined as ? 2 RBC units required in the 8 weeks prior to starting in the study).
Hemoglobin >= 8 g/dL (80 g/L) within 14 days prior cycle 1, day 1 (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
Have a hemoglobin ?9.0 g/dL without red blood cell transfusion for ?1 month.
Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)
Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)
Hemoglobin >8.0 mg/dL without red blood cell transfusion ? 3 days prior to C1D1
Hemoglobin >= 9.0 g/dL (with or without red blood cell [RBC] transfusion)
Hemoglobin ?8 g/dL, with no red blood cell (RBC) transfusions within the prior 14 days.
Hemoglobin >= 10 g/dL (not requiring red blood cell [RBC] transfusions)
Prior Red blood cell (RBC) transfusion < 3 months prior to starting CC-90002.
Hemoglobin 8.0 g/dL (may receive red blood cell [RBC] transfusions)
Patients must have symptomatic anemia untransfused with hemoglobin =< 9.5 g/dL within 8 weeks of registration or with red blood cell (RBC) transfusion-dependence (i.e., >= 2 units/month) confirmed for a minimum of 8 weeks before randomization
Hemoglobin < 9 g/dL (< 5.5 mmol/L; previous red blood cell [RBC] transfusion is permitted)
Hemoglobin ?9.0 g/dL (must be >2 weeks post-red blood cell transfusion)
Hemoglobin ? 8.0 g/dl (red blood cell (RBC) transfusions are permitted)
Within 3 days before the first dose of study drug: hemoglobin > 8 g/dL (prior red blood cell [RBC] transfusion allowed); patients may be transfused to achieve this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed
Hemoglobin ? 8 g/dL (red blood cell [RBC] transfusion is allowed)
Hemoglobin >= 8.0 g/dl (red blood cell [RBC] transfusions are permitted) must be met during screening (within 21 days) and also prior to study drug administration on cycle 1 day 1
Hemoglobin >= 8 g/dL without red blood cell transfusions within 2 weeks of the initiation of treatment
Hemoglobin >= 8.0g/dl (may receive red blood cell [RBC] transfusions)
Subjects who are not willing to receive red blood cell (RBC) transfusions to treat low hemoglobin levels
Hemoglobin >= 10.0 gm/dL (may receive red blood cell count [RBC] transfusions)
Hemoglobin >= 8 g/dL performed within 10 days of treatment initiation (red blood cell [RBC] transfusions are OK)
RBC transfusion-dependent anemia defined as: anemia requiring RBC transfusions of at least 1 unit of RBC every 6 weeks for hemoglobin =< 9.0 g/dL
Hemoglobin >= 10 g/dL (not requiring red blood cell [RBC] transfusions)
PART 2 GROUP 1 INCLUSION CRITERIA: Hemoglobin (Hgb) >= 8 g/dL (may receive red blood cell [RBC] transfusion)
Anemia or red blood cell (RBC)-transfusion dependence defined as follows: a) Anemia: defined for the purpose of this protocol as 1) a hemoglobin level < 10 g/L on every determination over 84 days before study-entry, without RBC-transfusions, or 2) a hemoglobin level < 10 g/L on a patient that is receiving RBC-transfusions periodically but not meeting criteria for transfusion-dependent patient as defined below; the baseline hemoglobin value for these subjects is the lowest hemoglobin level during the antecedent 84 days; b) RBC-transfusion-dependence: RBC-transfusion-frequency of >= 2 units packet red blood cell (PRBC)/28 days averaged over 84 days immediately pre-study-entry; there must not be any consecutive 42 days without an RBC-transfusion during this interval
Hemoglobin >= 8.0 mg/dL without red blood cell transfusion =< 7 days prior to C1D1
Hemoglobin >= 8 g/dL without red blood cell transfusions within 2 weeks of the initiation of treatment
Hgb < 10.0 g/dL (unless the hemoglobin value has been stable, the subject is cardiovascularly stable, asymptomatic and judged able to withstand the RFA procedure) Note: If clinically indicated, subjects may receive platelets or packed red blood cell (RBC) transfusions and be re-evaluated after condition is treated.
Hemoglobin >= 8 g/dL (80 g/L) (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
Hemoglobin >= 8 g/dL (80 g/L) within 14 days prior to starting therapy (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
Patients may receive red blood cell (RBC) or platelet transfusions, if clinically indicated, in accordance with institutional guidelines
Anemic patient OR red blood cell (RBC)-transfusion-dependent patient
Hemoglobin (>=) 7.5 gram per deciliter (g/dL) ([>=] 5 millimole per liter [mmol/L]; prior red blood cell [RBC] transfusion is permitted)
Hemoglobin >= 8 g/dL; subjects may receive red blood cell transfusions as clinically indicated per institutional guidelines but screening hemoglobin should be independent of red blood cell transfusion for at least 3 days prior to cycle 1 day 1
Hemoglobin >= 8 g/dL; red blood cell transfusions are permitted to meet eligibility criteria
Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin greater than 8 g/dL (may have received red blood cell [RBC] transfusions allowed)
For patients with solid tumors without bone marrow involvement: hemoglobin >= 8.0 gm/dL (may receive red blood cell [RBC] transfusions)
For patients with solid tumors without known bone marrow involvement: hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin >= 10.0 g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin ? 8 g/dL (80 g/L) within 14 days prior to randomization (subjects may be\n             receiving red blood cell [RBC] transfusions in accordance with institutional\n             guidelines)
Hemoglobin ? 9 g/dL. Patients may receive red blood cells (RBC) and/or erythropoietin (EPO) and/or platelet transfusions in accordance with institutional guidelines.
Red blood cell (RBC) transfusion dependent, 1) Received at least 4 units of RBCs over any 8 consecutive weeks during the 16 weeks prior to randomization, 2) Pretransfusion Hb must have been less than or equal to (<=)9.0 gram per deciliter (g/dL)
Patients who have received hematopoietic growth factor support within 14 days of day 1 of ibrutinib; patients who are Jehovah’s witnesses may be given an erythropoiesis-stimulating agent before and during the trial in lieu of red blood cell transfusions but anemia and/or red blood cell (RBC) transfusion dependence cannot be used for response assessment in these patients
Hemoglobin (Hgb) >= 9.0 g/dL (no red blood cell [RBC] transfusion within past 14 days)
Hemoglobin ?8 g/dL and no red blood cell (RBC) transfusions during the prior 14 days
Red blood cell (RBC) transfusion dependent, defined as requiring at least 4 RBC units transfused over an 8-week period during the 16 weeks prior to Study Entry; pre-transfusion hemoglobin (Hb) should be less than or equal to 9.0 gram per deciliter (g/dL) to count towards the 4 units total
Hemoglobin ? 8.0 g/dL (Use of erythropoietic stimulating factors and red blood cell [RBC] transfusion per institutional guidelines is allowed, however the most recent RBC transfusion may not have been done within 7 days prior to obtaining screening hemoglobin.)
Hemoglobin >= 8.0 g/dl (may receive red blood cell [RBC] transfusions)
Hemoglobin (Hgb) >= 9 g/dL and no red blood cell (RBC) transfusion within the past 14 days prior to study registration
Hemoglobin > 9 g/dL (80 g/L) within 30 days prior to cycle 1 day 1 (subjects may be receiving red blood cell transfusions in accordance with institutional guidelines)
Hemoglobin < 8g/dL (<4.9 mmol/L; prior red blood cell [RBC] transfusion is permitted)
Hemoglobin >= 8 g/dL (80 g/L) within 14 days prior to initial treatment (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
Hemoglobin > 9 g/dL (80 g/L) within 7 days of time of consent (subjects may be receiving red blood cell transfusions in accordance with institutional guidelines)
Hematocrit =< 28% or hemoglobin =< 9 g/dL (but may have red blood cell [RBC] transfusion)
Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin >= 9 g/dL; subjects may not have had a red blood cell (RBC) transfusion within 7 days of screening assessment
Hemoglobin >= 9.0 mg/dL without red blood cell transfusion =< 7 days prior to cycle 1 day 1 of therapy
Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin ? 9.0 g/dL and not requiring > 1 unit red blood cell transfusion per month; subjects receiving therapeutic erythropoietin preparations in accordance with the FDA product label are eligible to enroll;
History of transfusions < 10 RBC units and must not be RBC transfusion dependent
Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin > 9.0 g/dL (patients are allowed to receive transfused red blood cells [RBC] to achieve this level)
Hemoglobin >= 8 g/dL (80 g/L) within 14 days prior to randomization (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
Hemoglobin >= 9 g/dl (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines)
Hemoglobin ? 8.0 g/dL within 21 days prior to randomization. Use of erythropoietic stimulating factors and red blood cell (RBC) transfusions per institutional guidelines is allowed, however most recent RBC transfusion may not have been done within 7 days prior to obtaining screening hemoglobin.
Hemoglobin ? 8 g/dL without red blood cell transfusion within 72 hours of screening.
6-MMP >= 12,000/8 x 10^8 red blood cell (RBC) within 21 days prior to enrollment
Hemoglobin (Hgb) >= 8 g/dL and no red blood cell (RBC) transfusion within the past 21 days prior to study registration
Received any red blood cell (RBC) transfusion within 28 days prior to randomization.
worsening hemoglobin should be ? 1.5 g/dL decrease from preinjectable HMA (HYPOMETHYLATING AGENT) baseline value in subjects not receiving RBC (RED BLOOD CELL) transfusions
meaningful worsening in RBC (RED BLOOD CELL) or platelet transfusion requirement Definition of stable disease is based on modified IWG (INTERNATIONAL WORKING GROUP) 2006 criteria:
Hemoglobin ? 9.0 g/dL (in the absence of red blood cell transfusions in the prior 14 days)
Hemoglobin >= 9.0 g/dL (may receive red blood cell [RBC] transfusions)
Hemoglobin (Hgb) greater than 8.0 g/dL (may have packed red blood cell [PRBC] transfusion)
Measured within 28 days prior to registration: hemoglobin >= 10.0 g/dL with no blood transfusions (packed red blood cells in the past 28 days is permitted)
Inability to receive HCT due to alloimmunization, defined as the inability to receive packed red blood cell (pRBC) transfusion therapy.
Blood (packed red blood cells, platelets) transfusions within 1 month prior to study start
Hemoglobin >= 8 g/dL (with or without packed red blood cell [PRBC] transfusion) and documented within 14 days prior to registration and within 14 days prior to the start of treatment
Within 14 days prior to registration: Hemoglobin >= 10 g/dL; patients may be transfused packed red blood cells (PRBCs) up to 1 week prior to when enrollment labs are drawn; on study, transfusions may be given as clinically indicated
Subjects should not have packed red blood cells (PRBC) or platelet transfusion within 14 days of the screening
Hemoglobin: >= 8.0 gm/dl (may transfuse peripheral red blood cells [PRBCs])
Patients who have had a whole blood transfusion within 120 days prior to enrollment. (Packed red blood cells and platelet transfusions are acceptable)
Within two weeks prior to enrollment: Hemoglobin >= 9 gm/dL and > 7 days since last red blood cell transfusion
Hemoglobin >= 9.0 g/dL (may receive packed red blood cell [prbc] transfusion)
Hemoglobin (Hgb) >= 9 g/dL with or without packed red blood cells (pRBC) transfusion
Patients may be transfused with packed red blood cells (PRBCs) up to 7 days prior to when enrollment labs are drawn to achieve Hgb >= 9.0 mg/dL
Platelet transfusion and packed red blood cell transfusion can also be given prior to the start of treatment and treatment to achieve a target plt >= 75,000/uL and hemoglobin of >= 8.5 g/dl, provided that patients have not received growth factors for at least 14 days prior to entering trial
UROTHELIAL CARCINOMA EXPANSION COHORT: Hemoglobin >= 10 g/dL in the absence of packed red blood cells transfusion 28 days prior to dosing OR > 9 g/dL, if the value is constant across 2 readings within 2 weeks in the absence of packed red blood cells transfusion 28 days prior to dosing
Patients must have hemoglobin >= 8.5 g/dl; platelet transfusion and packed red blood cell transfusion can also be given prior to the start of treatment and during treatment to achieve a target hemoglobin of >= 8.5/ul provided that patients have not received growth factors for at least 14 days prior to entering trial
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nHemoglobin (Hgb) >= 10 g/dL in the absence of packed red blood cell transfusion 28 days prior to dosing OR Hgb 9-9.9 g/dL and the value is constant across 2 readings within 2 weeks, in the absence of packed red blood cell transfusion 28 days prior to dosing
PHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHemoglobin (Hgb) >= 9 g/dL in the absence of packed red blood cell transfusion 28 days prior to dosing
PHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT 4 ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHemoglobin (Hgb) >= 9 g/dL in the absence of packed red blood cell transfusion 28 days prior to dosing
PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nHemoglobin (Hgb) >= 9 g/dL in the absence of packed red blood cell transfusion 28 days prior to dosing
Hemoglobin >= 9 g/dL (packed red blood cell [pRBC] transfusion +/- erythropoiesis-stimulating agents [ESA] are allowed) (must be within 7 days of MLA)
Hemoglobin >= 8 g/dL (packed red blood cell [PRBC] transfusions permitted)
Hemoglobin (Hgb) greater than 8.0 g/dL (may have packed red blood cell [PRBC] transfusion)
Part 1: hemoglobin level of ? 8 g/dL within 2 weeks of enrollment\r\n* Packed red blood cell (PRBC) transfusions will be allowed to patients with hemoglobin < 8g/dl
Hemoglobin >= 8 g/dL (packed red blood cells [PRBC] transfusions permitted)
Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L, specimens must be collected within 10 days prior to the start of study treatment\r\n* Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks
Hemoglobin >= 8 g/dl (may be after transfusion of packed red blood cells or use of erythropoiesis stimulating agents)
Absence of a regular red blood cell transfusion requirement
Hemoglobin >= 8.0 gm/dL (may receive packed red blood cell [PRBC] transfusions)
Platelet or packed red blood cell transfusion within 14 days of pre-treatment evaluation
Hemoglobin >= 9 (packed red blood cells [pRBC] transfusion +/- erythropoiesis-stimulating agents [ESA] are allowed) (must be within 7 days of MLA)
Previous major bleed (bleeding requiring transfusion of red blood cells) on LMWH
Hemoglobin >= 8 g/dL (may have received packed red blood cell transfusion)
Within 14 days after subjects signed the treatment consent: Hemoglobin >= 10 g/dl; patients may be transfused packed red blood cells (PRBCs) up to 1 week prior to when enrollment labs are drawn; on study, transfusions may be given as clinically indicated
Hemoglobin >= 9 g/dl (may transfuse packed red blood cells [PRBC] to meet parameter)
Packed red blood cell or platelet transfusion within 7 days of screening laboratory tests.
Hemoglobin >= 9 g/dl without packed red blood cell dependency, unless due to bone marrow involvement with lymphoma
Red blood cell transfusion within 2 weeks prior to anticipated start of study treatment.
Anemia, Hemoglobin (Hgb) ? 9.0 g/dL or ? 2 units of Red Blood Cells (RBCs) within 84 days
Packed cell volume (PCV) >= 30 (with or without transfusion)
Hemoglobin >= 8.0 gm/dL (may receive packed red blood cell [pRBC] transfusions)
